White & Case with Takeda in asset sale to Hikma and Esteve
White & Case has assisted Takeda Pharmaceutical Company Limited (Takeda) in two separate transactions: the first involves the divestment of a portfolio of pharmaceutical products, currently licensed and marketed by Hikma Pharmaceuticals PLC (Hikma), for certain territories in the Middle East and North Africa (MENA) region; the second transaction involves the divestment of the oncology product MEPACT (mifamurtide) to Esteve Pharmaceutical (Esteve).
Both divestments are subject to customary conditions precedent and antitrust approvals, and are expected to close during 2025.
Takeda is a leading global biopharmaceutical company based in Japan, focusing on gastroenterology, rare diseases, plasma-derived therapies, oncology, and neuroscience. Hikma is a UK-listed global pharmaceutical company with presence in North America, MENA, and Europe. Esteve is a global pharmaceutical company based in Spain with a presence in Europe.
The White & Case team that advised Takeda was led by partners Michael Immordino (London and Milan) and Leonardo Graffi (Milan and London) and included partners Philip Trillmich (Frankfurt) and Strati Sakellariou-Witt (Brussels), along with associates Tommaso Poli and Giulio Preti (both from the Brussels office).
